Achillion Pharmaceuticals, Inc. (ACHN), one of last weeks top percentage-gainers, was upgraded this morning by analysts at Deutsche Bank (DB) to a ‘Buy’ rating from a ‘Hold’ rating. The research firm also raised its price target on the stock to $17 from $6 a share, which represents a potential upside of 83.78% from its Friday close.
ACHN has been the subject of a number of other recent research reports. Analysts at Piper Jaffray upgraded their rating on shares of Achillion Pharma from ‘Neutral’ to ‘Overweight’, placing an $11.00 price target in a research note to clients on Monday, August 11. Separately, analysts at JMP Securities upgraded their rating on ACHN from ‘Market Perform’ to ‘Market Outperform’ and price target of $13.00 per share in a research note on August 8. Finally, Baird and UBS analysts raised their rating on shares of the pharmaceuticals company to ‘Outperform’ from ‘Neutral’ and ‘Buy’ to ‘Neutral’, respectively, on a research note to clients and investors on Wednesday, June 11.
On valuation-measures, shares of Achillion Pharmaceuticals have a t-12 negative return on equity of 38.97%. EPS is also negative at $0.65. The company has a market cap of $904.54 million and a median Wall Street price target of $11.50 with a high target of $22.00. Achillion last announced its earnings results on August 7th, reporting a Q2’14 net loss of $15.7 million compared with a net loss of $19.9 million during the same period of FY2013.
ACHN has a beta of 1.80 and a short float of 35.20%. In the past 52 weeks, shares of Achillion have traded between a low of $2.26 and a high of $9.94. The pharma company reported $131.47 million in cash vs. $164.000 in debt in its most recent quarter.
ACHN is currently printing a one year return of about 42% and a year-to-date return of around 178.7%.
The chart below shows where the equity has traded over the last 52 weeks, with the 50-day and 200-day MAs included.
ACHN is currently trading up 6.70% to $9.80 at 7:47 a.m. in New York. The stock closed the week up $9.25, or +20%.
Achillion Pharmaceuticals, Inc. develops and commercializes anti-infective drug therapies in the U.S. and internationally. The firm was founded in 1998 and is headquartered in New Haven, Connecticut.